Research Article

Research on the Mechanism of Liuwei Dihuang Decoction for Osteoporosis Based on Systematic Biological Strategies

Zhi-yong Long,1 Jia-min Wu,2 Wang Xiang,2 Meng-xia Yuan,2 Yong-he Wu,2 Jun Li,3 Gan-peng Yu,3 and Tiejun Yang3

1Department of Rehabilitation Medicine, Guangzhou Panyu Central Hospital, Guangzhou, China
2Hunan University of Chinese Medicine, Changsha, Hunan, China
3People’s Hospital of Ningxiang City, Ningxiang 410600, Hunan, China

Correspondence should be addressed to Zhi-yong Long; 2212471438@qq.com

Received 16 May 2021; Revised 21 February 2022; Accepted 11 May 2022; Published 22 September 2022

Academic Editor: Adolfo Andrade-Cetto

Copyright © 2022 Zhi-yong Long et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Osteoporosis is an important health problem worldwide. Liuwei Dihuang Decoction (LDD) and its main ingredients may have a good clinical effect on osteoporosis. Meanwhile, its mechanism for treating osteoporosis needs to be further revealed in order to provide a basis for future drug development. Methods. A systematic biological methodology was utilized to construct and analyze the LDD-osteoporosis network. After that, the human transcription data of LDD intervention in patients with osteoporosis and protein arrays data of LDD intervention in osteoporosis rats were collected. The human transcription data analysis, protein arrays data analysis, and molecular docking were performed to validate the findings of the prediction network (LDD-osteoporosis PPI network). Finally, animal experiments were conducted to verify the prediction results of systematic pharmacology. Results. (1) LDD-osteoporosis PPI network shows the potential compounds, potential targets (such as ALB, IGF1, SRC, and ESR1), clusters, biological processes (such as positive regulation of calmodulin 1-monoxygenase activity, estrogen metabolism, and endothelial cell proliferation), and signaling and Reactome pathways (such as JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) of LDD intervention in osteoporosis. (2) Human transcriptomics data and protein arrays data validated the findings of the LDD-osteoporosis PPI network. (3) The animal experiments showed that LDD can improve bone mineral density (BMD), increase serum estradiol (E2) and alkaline phosphatase (ALP) levels, and upregulate Wnt3a and β-catenin mRNA expression (P < 0.05). (4) Molecular docking results showed that alois A, dioxin, loganin, oleanolic acid, pachymic acid, and urso acid may stably bind to JAK2, ESR1, and CTNNB1. Conclusion. LDD may have a therapeutic effect on osteoporosis through regulating the targets (such as ALB, IGF1, SRC, and ESR1), biological processes (such as positive regulation of calmodulin 1-monoxygenase activity, estrogen metabolism, and endothelial cell proliferation), and pathways (such as JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) found in this research.

1. Introduction

Osteoporosis is a common systemic metabolic bone disease with a decrease in bone density and bone quality and bone microstructural damage caused by various reasons [1]. The serious clinical outcome of osteoporosis is osteoporotic fractures (fragility fractures), which lead to a significant increase in morbidity and mortality in patients with osteoporosis [2]. The treatments for osteoporosis include the following: (1) basic prevention, such as lifestyle adjustment (diet and outdoor sports) and basic bone health supplements (calcium and vitamin D); (2) drug interventions, such as antbone resorption drugs (bisphosphonates, calcitonin, selective estrogen receptor modulators (SERMs), and estrogen); (3) drugs that promote bone formation, such as targeted drugs [2–4]. However, recent studies showed that the preventive and therapeutic effects of the above drugs are still controversial, such as vitamin D [5], while antbone resorption drugs increase the burden of medical resources and reduce patient compliance due to their high price [6].
Natural plant products have become the direction of new drug development due to their multicomponent, multitarget features and cheap price [7, 8].

Traditional Chinese medicine (TCM), as a traditional medicine applied for thousands of years, has gradually highlighted its therapeutic advantages in osteoporosis through long medical clinical practice [8]. Liuwei Dihuang Decoction (LDD) as a representative of TCM for the treatment of osteoporosis, comes from Jingyue Quanshu. This formula is composed of *Rehmannia glutinosa* (Gaertn.) DC (Rehmanniae Radix Praeparata, Dihuang), *Cornus Officinalis* Sieb. et Zucc. (Shanzhuyu), *Paonia × suffruticosa* Andrews (Cortex Moutan, Mudanpi), *Dioscorea oppositifolia* L. (Rhizoma Dioscoreae, Shanyao), *Poria cocos* (Schw.) Wolf. (Fuling), and *Alisma plantago-aquatica* L. (Alisma orientale (Sam.) Juz., Zexie). Current clinical studies showed that LDD alone or in combination with other anti-osteoporosis drugs (alendronate, salmon calcitonin) for osteoporosis has a certain effect: it can effectively improve the patient’s bone density (in the lumbar spine, the femoral neck, the distal third of the junction, and the tibia bone density) and the clinical efficacy rate [9, 10]. A systematic review and meta-analysis also showed that LDD can increase the bone mineral density of the hip, lumbar spine, ulna, and radius, and it has a good effect in improving the effective rate of clinical treatment of postmenopausal osteoporosis and reducing the pain caused by osteoporosis [11]. Its mechanism may be related to the regulation of hormone levels and oxidative stress through the Wnt/β-catenin signaling pathway [12, 13]. In addition, current pharmacological studies showed that LDD has the effect of inhibiting aging and prolonging the lifespan of *C. elegans* life-sustaining and natural aging mice [14]. However, its mechanism for treating osteoporosis needs to be further revealed in order to provide a basis for future drug development.

Systemic pharmacology is a discipline that studies the effects of drugs on disease at a system level, which combines multidisciplinary technologies such as bioinformatics and network pharmacology to bring new strategies for analyzing the mechanism of drugs [15, 16]. This method can resolve multicom pound and multitarget drugs from microscopic (molecular and biochemical network level) to macroscopic (tissue, organ, and overall level) levels [15, 16]. Meanwhile, at present, researchers have explored the therapeutic mechanisms of natural products for disease through systematic pharmacology [17–20]. Therefore, in this research, the systematic pharmacological methodology would be utilized to uncover the mechanism of LDD on osteoporosis. The process of this study is shown in Figure 1.

### 2. Materials and Methods

#### 2.1. LDD’s Compounds Prediction

The TCM Database@ Taiwan [21] (https://tcmd.cmu.edu.tw/zh-tw/) and the TCMSP database [22] (https://tcmspw.com/tcmsp.php) were utilized to collect the compounds of LDD. Then, in order to predict the bioactive compounds of LDD, oral bioavailability (OB), Caco-2 permeability, and drug-likeness (DL) were applied [17, 18]. The standard was OB ≥30%, Caco-2 >0.4, and DL ≥0.18 [21]. The components meeting this standard was included. Meanwhile, due to the limitations of prediction methods based on pharmacokinetic parameters [23], in order to avoid losing potential active components, we searched a large amount of literature [24–28] to collect compounds that are orally absorbable and biologically active. The pharmacokinetic parameters of the components are shown in Table 1.

#### 2.2. LDD’s Potential Target Prediction and Osteoporosis Genes Collection

The molecular structures of each compound were collected from the PubChem (https://pubchem.ncbi.nlm.nih.gov/) and the SciFinder (https://scifinder.cas.org/) and saved as “sdf” file format. These “sdf” files of each compound were input into PharmMapper (https://lilab-ecust.cn/pharmmapper/) to predict the potential targets [29]. The name of the target protein was imported into UniProtKB (https://www.uniprot.org/), and the species was limited to “*Homo sapiens*,” so that the name of the protein was corrected to their official symbols (see Table S1 in Supplementary Materials). Meanwhile, the OMIM database (https://omim.org/) and GeneCards (https://www.genecards.org/) were utilized to collect the osteoporosis-related disease genes and targets with the keyword “Osteoporosis” [17, 18]. The osteoporosis-related genes and their relevance scores are shown in Table S2.

#### 2.3. Human Transcriptome Data and Protein Arrays Data Collection

Transcriptome data come from GEO (https://www.ncbi.nlm.nih.gov/geo/). The data on LDD treating osteoporosis were obtained from GSE57273. The protein arrays data of LDD intervention in osteoporosis rats come from [30]. Differential expression analysis was performed using the R software package.

#### 2.4. Network Construction and Analysis Methods

The protein-protein interaction (PPI) data were collected from String database (https://string-db.org/) with medium confidence >0.4 and the IntAct database (https://www.ebi.ac.uk/intact/) [31, 32]. The LDD targets, osteoporosis genes, and their PPI data were input into Cytoscape 3.7.0 (https://cytoscape.org/) for network construction and analysis [33]. In the PPI network, there are dense areas of some molecular complexes, which are defined as clusters [33]. Clusters can be viewed as functional modules, and drugs may treat diseases by regulating these functional modules. The cluster was obtained by analyzing the network using MCODE, a plug-in of Cytoscape software.

#### 2.5. Gene Ontology (GO), Signaling Pathway, and Reactome Pathway Enrichment Analysis

The LDD targets, osteoporosis genes, human transcriptome data, and protein arrays data were input into the DAVID database ver. 6.8 (https://david-d.ncifcrf.gov) for GO enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis [34]. GO enrichment analysis
includes biological processes, cell components, and molecular function. Meanwhile, those data were input into the Reactome Pathway Database (https://reactome.org/) for Reactome pathway enrichment analysis [35].

2.6. Experimental Materials

2.6.1. Instruments and Reagents. LDD (Approval number: National Pharmaceutical Standard Z11020056) was purchased from Beijing Tongrentang Technology Development Co., Ltd. Alendronate sodium (Approval no. National Pharmaceutical Standard J20130085) was purchased from Hangzhou Merck Pharmaceutical Co., Ltd. Estradiol (E2), alkaline phosphatase (ALP), enzyme-linked immunosorbent assay (ELISA) kit were purchased from Beijing Northern Biotechnology Research Institute Co., Ltd. (lot number: 180820, 180416). Dual-energy X-ray absorptiometry was purchased from General Electric Company. Wnt3a, β-catenin, and β-actin primers were synthesized by Shanghai Shengong Biotechnology Co., Ltd.

2.6.2. Experimental Animal. In total, 40 healthy SD female rats, 180–240 days old, were provided by Hunan Slake Jingda Experimental Animal Co., Ltd. [Animal License Number: SYXK(Xiang)2018-0002] and were raised in the Experimental Animal Center of Hunan University of Chinese Medicine. The animals were weighed, numbered, and divided into 4 groups according to the random sequence method: sham operation group (10 rats), model group (10 rats), LDD group (10 rats), and positive control group (10 rats). Animal experiments have been approved by the Animal Ethics Committee of Hunan University of Chinese Medicine (Approval no. HUTCM-LL20199306) and performed in accordance with the guidelines for the care and use of experimental animals.

2.7. Experimental Methods

2.7.1. Animal Modeling and Intervention. After 1 week of adaptive feeding, rats underwent bilateral ovarian resection under anesthesia (3% pentobarbital sodium 30 mg/kg intraperitoneal injection) to create postmenopausal osteoporosis (PMOP) model. On the 7th day after the operation, the rats began to administer the medicine by gavage daily. The sham operation group and the model group were intragastrically administered with 10 mL/kg of normal saline. The rats in the LDD group were gavaged with LDD 6.75 g crude drug/kg. The rats in the positive control group were gavaged with alendronate sodium 0.1 mg/mL.

2.7.2. Specimen Collection and Processing. Under anesthesia with 3% pentobarbital sodium 30 mg/kg, blood was collected from the abdominal aorta. After the blood was placed at room temperature for 1 hour, the blood was centrifuged at 3
### Table 1: The pharmacokinetic parameters of components.

| Molecule | OB (%) | Caco-2 (%) | DL (%) |
|----------|--------|------------|--------|
| Sitossterol | 36.91 | 1.32 | 0.75 |
| Stigmasterol | 43.83 | 1.44 | 0.76 |
| Paeoniflorin | 68.18 | –0.34 | 0.4 |
| Mairin | 55.38 | 0.73 | 0.78 |
| Kaempferol | 41.88 | 0.26 | 0.24 |
| (+)-Catechin | 54.83 | –0.03 | 0.24 |
| 4-O-Methylpaeoniflorin | 67.24 | 0.15 | 0.43 |
| 5-[(4-Methoxyphenyl)-2-furyl]-methylene|barbituric acid (ZINC02816192) | 43.44 | 0.09 | 0.3 |
| Mudanpioside H | 42.36 | –0.39 | 0.37 |
| Paeonidin | 65.31 | –0.09 | 0.35 |
| Quercetin | 46.43 | 0.05 | 0.28 |
| (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-Dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopta[a]phenanthren-17-yl]-6-methylepht-5-enolic acid (MOL000273) | 30.93 | 0.01 | 0.81 |
| Trametenolic acid | 38.71 | 0.52 | 0.8 |
| 7,9 (11)-Dehydroachaemic acid | 35.11 | 0.03 | 0.81 |
| Cerevisitol | 37.96 | 0.28 | 0.77 |
| (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-Dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enolic acid (MOL00280) | 31.07 | 0.05 | 0.82 |
| Ergosta-7,22E-dien-3beta-ol | 43.51 | 1.32 | 0.72 |
| Ergosterol peroxide | 40.36 | 0.84 | 0.81 |
| (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-Dihydroxy-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enolic acid (MOL000285) | 38.26 | 0.12 | 0.82 |
| 3beta-Hydroxy-24-methylene-8-lanostene-21-oic acid (MOL000287) | 38.7 | 0.61 | 0.81 |
| Pachymic acid | 33.63 | 0.1 | 0.81 |
| Poricoic acid A | 30.61 | –0.14 | 0.76 |
| Poricoic acid B | 30.52 | –0.08 | 0.75 |
| Poricoic acid C | 38.15 | 0.32 | 0.75 |
| Hederagenin | 36.91 | 1.32 | 0.75 |
| Dehydroeburicoic acid | 44.17 | 0.38 | 0.83 |
| Piperlongumine | 30.71 | 0.95 | 0.18 |
| (-)-Taxifolin | 60.51 | –0.24 | 0.27 |
| Denudatin B | 61.47 | 0.9 | 0.38 |
| Kadsurenone | 54.72 | 0.82 | 0.38 |
| Hacnolin | 64.01 | 0.53 | 0.37 |
| Hacninoine C | 59.05 | 0.74 | 0.39 |
| Campesterol | 37.58 | 1.34 | 0.71 |
| Isoflucosterol | 43.78 | 1.36 | 0.76 |
| Dioscoreside C | 36.38 | 0.39 | 0.87 |
| Diosgenin | 80.88 | 0.82 | 0.81 |
| Doradexanthin | 38.16 | 0.52 | 0.54 |
| Methylicminicfugoside | 31.69 | 0.21 | 0.24 |
| AIDS180907 | 45.33 | 0.73 | 0.77 |
| CLR | 37.87 | 1.43 | 0.68 |
| Mandenol | 42 | 1.46 | 0.19 |
| Ethyl linolenate | 46.1 | 1.54 | 0.2 |
| Poriferas-5-en-3beta-ol | 36.91 | 1.45 | 0.75 |
| Diop | 43.59 | 0.79 | 0.39 |
| Ethyl olate (NF) | 32.4 | 1.4 | 0.19 |

### Table 1: Continued.

| Molecule | OB (%) | Caco-2 (%) | DL (%) |
|----------|--------|------------|--------|
| Malkangunin | 57.71 | 0.22 | 0.63 |
| 2,6,10,14,18-Pentamethylcicosa-2,6,10,14,18-pentane (MOL005481) | 33.4 | 1.94 | 0.24 |
| 3,4-Dehydrolycopen-16-ol | 46.64 | 2 | 0.49 |
| Conurudentonone | 39.66 | 0.47 | 0.33 |
| Hydroxyogenkwanin | 36.47 | 0.52 | 0.27 |
| Telocinobufagin | 69.99 | –0.12 | 0.79 |
| Tetrahydroalstonine | 32.42 | 0.9 | 0.81 |
| Lanosta-8,24-dien-3-ol,3-acetate | 44.3 | 1.45 | 0.82 |
| Alisol B | 34.47 | 0.04 | 0.82 |
| Alisol B23 acetate | 32.52 | –0.06 | 0.82 |
| Alisol C | 32.7 | –0.34 | 0.82 |
| Acteoside* | 2.94 | –1.89 | 0.62 |
| Catalpol* | 5.07 | –1.72 | 0.44 |
| Rehmannioside A* | 25.95 | –3 | 0.87 |
| Rehmannioside D* | — | — | — |
| Stachyose* | 3.25 | –5.54 | 0.59 |

*Components supplemented according to literature.

500 r/min for 15 minutes. The serum was separated and stored in a refrigerator at –80°C. The right femur of the rat was stored at –20°C for bone density detection and Quantitative Real-time PCR (qRT-PCR). The left femoral head of the rat was fixed with 4% paraformaldehyde for HE staining.

#### 2.7.3. Serum E2, ALP Level, and Bone Mineral Density (BMD) Detection.

Serum E2 and ALP were detected by ELISA. BMD was measured by a dual-energy X-ray bone densitometer.

#### 2.7.4. Histopathological Observation.

The left femoral head was fixed with a volume fraction of 4% paraformaldehyde for 72 h and then decalcified with 10% EDTA decalcification solution, and the decalcification solution was changed every 3 days. After decalcification was completed, it was rinsed with PBS, dehydrated with gradient ethanol, cleared with xylene, embedded in paraffin, and sliced for HE staining. The histopathological changes in the femoral head were observed under a light microscope.

#### 2.7.5. Genetic Testing Methods.

Blood RNA was extracted and reverse-transcribed into cDNA for qRT-PCR detection. Reaction system was as follows: PCR forward primer (2μM) 2 μL; PCR reverse primer (2μM) 2μL; 2X All-in-One qPCR Mix 10 μL; Template 2 μL; 50X Rox Reference Dye 0.4 μL; ddH2O 3.6 μL; total 20 μL. The reaction conditions were set as follows: pre-denaturation: 95°C 10 min, 1 cycle; amplification reaction: 95°C 10 s, 62°C 20 s, 72°C 15 s, 45 cycles; draw melting curve: 95°C 10 s, 25°C 30 s. Each sample was repeated 3 times. For data analysis, the 2−ΔΔCt method was used to calculate the difference in Wnt3a and β-catenin gene mRNA transcription levels. The gene sequence was searched in the NCBI database, and primers were designed, as shown in Table 2.
2.8. Statistical Analysis. SPSS22.0 software was used for statistical analysis. The measurement data are expressed by mean ± standard deviation (x ± s), and the comparison between groups adopts multiasample mean comparison and analysis of variance. The test level adopts α = 0.05; P < 0.05 indicates that the difference is statistically significant.

2.9. Molecular Docking Validation. The top 6 components in the compound-compound target network of LDD were selected as ligand, and ESR1, β-catenin (CTNNB1), and JAK2 were selected as receptors. The “.sdf” format file of the top 6 components was input into ChemBioDraw for energy minimization and saved as “.mol2” format. The PDB database (https://www.rcsb.org/) was used to retrieve the 3D structure of ESR1 (PDB ID: 1QKT), CTNNB1 (PDB ID: 1JDH), and JAK2 (PDB ID: 3E62) [36]. Discovery Studio Client Ver. 4.5 software was used to hydrogenate proteins, remove water, and remove ligand molecules. Auto Dock v. 4.2 software was used for molecular docking. The binding energy ≤-5.0 kJ/mol was used as a standard to screen ligand-receptor molecules that can bind stably [37–39].

3. Results and Discussion

3.1. Osteoporosis Genes and the Potential Targets of LDD.

Two thousand and nine hundred and eighty-three osteoporosis genes were obtained from GeneCards and OMIM database. The osteoporosis genes with a relevance score ≥5.0 were selected to construct the LDD-osteoporosis PPI network (see Table S2). A total of 423 LDD potential targets were predicted from PharmMapper. The relationship between LDD compounds and LDD potential targets is shown in Figure 1, which consists of 423 compound targets, 68 compounds, and 1009 edges. In Figure 2, targets near the center are regulated by more compounds, whereas targets near the periphery are regulated by fewer compounds. For example, HSP90AA1, CDK2, GSTP1, AKR1B1, BACE1, CA2, F2, LCK, and GSTA1 are regulated by all compounds; ACE2 can be only regulated by chlorogenic acid.

3.2. LDD-Osteoporosis PPI Network Analysis

3.2.1. LDD-Osteoporosis PPI Network. The target shared by LDD potential target and osteoporosis genes is LDD-osteoporosis targets. The LDD-osteoporosis PPI network contains 743 nodes (379 LDD target nodes, 35 LDD-osteoporosis nodes, and 329 osteoporosis genes nodes) and 8081 edges (Figure 3). After analysis of the LDD-osteoporosis PPI network, it was found that LDD can directly and indirectly regulate the core target of osteoporosis. The top 20 targets are selected and divided into three categories: (1) osteoporosis genes: INS (300 edges), TP53 (248 edges), IL6 (245 edges), TNF (207 edges), MAPK3 (202 edges), EGF (199 edges), JUN (166 edges), CTNNB1 (161 edges), and CCND1 (149 edges); (2) LDD targets: AKT1 (253 edges), EGFR (205 edges), MAPK1 (181 edges), MMP9 (165 edges), MAPK8 (161 edges), HRAS (151 edges), and CASP3 (150 edges); (3) LDD-osteoporosis targets: ALB (275 edges), IGF1 (187 edges), SRC (173 edges), and ESR1 (168 edges).

3.2.2. Clusters of LDD-Osteoporosis PPI Network. The Cytoscape’s plug-in MCODE was utilized to analyze the LDD-osteoporosis PPI network, and 13 clusters were obtained (Table 3 and Figure 4). The targets and genes in clusters were input into the DAVID database to undergo GO enrichment analysis.

Cluster 1 is mainly involved in several signaling pathways in osteoporosis (such as MAPK, PI3K, and JAK-STAT signaling pathway) and positive regulation of calmodulin 1-monoxygenase activity, estrogen metabolism, endothelial cell proliferation, and neovascularization during bone remodeling. Cluster 2 is mainly involved in endothelial cell proliferation in bone remodeling, differentiation of osteoblasts and chondrocytes, bone resorption, and some signaling pathways (such as PI3K, MAPK, NF-κB, TGF-beta/SMAD, BMP, and Wnt signaling pathway). Cluster 3 is associated with bone resorption and reconstruction, mesenchymal cell differentiation, osteoblast differentiation, osteogenic matrix, and osteoporosis-related signaling pathways (BMP, Wnt, and TGF-β signaling pathway). Cluster 4 is mainly involved in endothelial cell proliferation in bone remodeling and differentiation of osteoblasts and chondrocytes. Cluster 6 is mainly related to steroid metabolism. Cluster 10 is related to steroid metabolism. Cluster 15 failed to return any human biological processes. Clusters 5, 7, 8, 9, 11, 13, 14, 16 and 17 do not return any osteoporosis-related biological processes. The details of each cluster and biological processes are described in Table S3.

Since cluster 1 is the most important one, it is used as an example to show its main biological processes on the bubble chart (Figure 5(a)).

3.2.3. Cell Components, Molecular Functions, and Signaling Pathway of LDD-Osteoporosis PPI Network. The LDD targets and osteoporosis in the LDD-osteoporosis PPI network were input into DAVID to collect cell component, molecular functions, and signaling pathways. The top 10 cell components were as follows: extracellular region, extracellular...
space, extracellular exosome, cytosol, ficolin-1-rich granule lumen, endoplasmic reticulum lumen, cytoplasm, secretory granule lumen, receptor complex, and membrane (Figure 5(b)). The top 10 molecular functions were as follows: identical protein binding, RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding, enzyme binding, zinc ion binding, transmembrane receptor protein tyrosine kinase activity, protein tyrosine kinase activity, protein homodimerization activity, protein binding, protein serine/threonine/tyrosine kinase activity, and ATP binding (Figure 5(c)). The top 10 pathways were as follows: FoxO signaling pathway, estrogen signaling pathway, osteoclast differentiation, PI3K-Akt signaling pathway, Ras signaling pathway, T-cell receptor signaling pathway, GnRH signaling pathway, metabolic pathways, and insulin signaling pathway (Figure 5(d)). The role of LDD in the Wnt signaling pathway is shown in Figure 5(e). The LDD targets are marked in red, the osteoporosis gene is marked in blue, and the LDD-osteoporosis is marked in purple (see Table S4).

Meanwhile, the compounds of *Cornus officinalis* Sieb. et Zucc. totally regulate 228 targets (which is the most), while those of *Rhizoma Dioscoreae* regulate 216 targets. The compounds of *Rhizoma Dioscoreae* and *Rhizoma*.
Dioscorea regulate 206 targets, respectively. This suggests that Cornus officinalis Sieb. et Zucc. and Rhizoma Dioscoreae play a major role in LDD (Figure 6).

3.2.4. Reactome Pathway of LDD-Osteoporosis PPI Network. The LDD targets and osteoporosis in the LDD-osteoporosis PPI network were input into Reactome Pathway Database to collect the Reactome pathways. These osteoporosis-related Reactome pathways were arranged according to the $P$-value from small to large, and it is found that interleukin-4 and interleukin-13 signaling is ranked first. According to the sorting, the other Reactome pathways (top 10) are as follows: Cytokine Signaling in Immune system, Signaling by Receptor Tyrosine Kinases, Negative regulation of the PI3K/AKT network, PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling, Interleukin-12 family signaling, SUMOylation of intracellular receptors, Interleukin-12 signaling, Extracellular matrix organization, and Degradation of the extracellular matrix. The top 30 Reactome pathways are shown in Figure 5(e). The details of each Reactome pathways are shown in Table S5.

At present, it was found that LDD has obvious anti-osteoporosis effect in ovariectomized rats, which is mainly achieved by activating the Wnt/β-catenin signaling pathway [40]. Ge et al. found that in patients with postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency, the therapeutic effect of LDD may be mediated through upregulation of CLCF1 gene and IRF1 gene expression and activation of JAK/STAT signaling pathway [12, 41]. Xu et al. found that LDD can significantly inhibit the methylation of ERα gene promoter and increase the expression of ERα mRNA and protein and promote the proliferation and differentiation of osteoblasts by AMPK and β-catenin signaling mediated by this pathway [42]. In addition, in exploring the plant estrogen activity of LDD, new studies have shown that in the ovariectomized rat model, enhanced...
estrogen activity occurs when combined with the soy diet with LDD [43]. Moreover, a large number of studies confirmed that the active compounds in LDD's herbs play an anti-osteoporosis role.

For example, Luo et al. found that Rehmanniae Radix Praeparata extract has osteoprotective effects, the mechanism of which is related to the IGF-1/Pi3K/mTOR pathway [44]. Lai et al. showed that Th1/Th2 skew is associated with bone loss caused by estrogen deficiency, and catalpol can effectively reduce bone loss by regulating Th1/Th2 balance [45]. Zhu et al. found that catalpol promotes osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/β-catenin pathway [46]. Ferulic acid can alter specific aspects of the bone epigenome to improve osteoblast differentiation, reduce osteoblast apoptosis, improve bone mineralization, and reduce osteoclast differentiation and function [47, 48]. Ferulic acid can also inhibit osteoclast fusion by inhibiting the expression of RANKL/DC-STAMP and induce apoptosis of mature osteoclasts via the caspase-3 pathway [49]. Paenonol can inhibit RANKL-induced osteoclastogenesis by inhibiting ERK, p38, and NF-κB pathways [50]. Further studies showed that its derivatives, YPH-PA3, promote the differentiation of precursor cells of the monocyte/macrophage lineage into osteoblasts and enhance their autophagy [51]. Kaempferol in LDD has a strong anti-osteoporosis effect [52–56]. Evidence from different teams showed the mechanism of acteoside against osteoporosis [57, 58]. Quercetin in LDD was also found to have

Table 3: Cluster of LDD-osteoporosis PPI network.

| Cluster | Score | Nodes | Edges | Targets and genes |
|---------|-------|-------|-------|-------------------|
| 1       | 32.962| 53    | 857   | JAK2, MET, MDM2, PPARG, GRB2, MAPK1, MMP2, TNF, EGFR, IL1B, APOE, BCL2L1, CCND1, AKT2, MMP1, LEPT, IGF2, IFNG, IGF, NO3S, TP53, PLAU, FOS, CDC42, REN, CCL5, MMP3, MMP7, JUN, HRAS, NR3C1, CRP, LOX, HSP90AA1, SELE, MMP9, CCNA2, RHOA, MAPK3, SRC, CAT, ANXA5, XIAP, ACE, IL10, RUNX2, IGF1R, MAPK14, PGR, AR, MAP2K1, HMOX1, LCK |
| 2       | 23.884| 70    | 824   | PTTPN1, PRL, GSK3B, SMAD3, ELANE, IL2, IL6, TGFBI, CASP3, LMA, PTTPN11, CASP1, PARP1, CSH, TERT, FBN1, SERPINA1, MEN1, ERBB4, SPPI, MMP13, ADAM17, PIK3R1, CP, PTK2, FGG, SOD2, NQO1, CTNNB1, MAPK8, ALPL, APOA2, STAT1, INS, MAPK10, NO3S, ADIPOQ, SP1, PTKB2, AB1L, IGF1, AKTI1, BMP15, IGFBP4, LAG153, IGFBP1, IGFBP5, MEPE, BMP4, CDK2, JAK3, TRAF6, ESRI, SPARC, CTSB, ESRI2, KIT, EIF4E, CD40LG, TF, HPGDS, KDR, BMP2, BGLAP, F2, RAF1, MMP14, ALB, TNFSF11, SOX9 |
| 3       | 9.901 | 82    | 401   | SP7, COL2A1, EPHA2, DPP4, HSPA8, TEK, HSPA1A, AURKA, BMP7, WNT3A, PTH, CTSG, GNRH1, LDLR, POMC, TGFBR1, SORT, PRKACA, FABP5, GM2A, BTK, IL1A, ACP5, CALR, RAC2, SELP, CHEK1, GG1T1, HEXB, JAG1, RHEB, CRH, GALNS, VCP, CYP19A1, PTBLH, RNASE2, CASP7, CSF1, DUSP6, IMDP1, FGFR2, IBSP, ELN, GSR, LEPR, IL1RN, RNASE3, ATIC, EIF2AK3, IZY, IL11, HCK, ZAP70, FGFR1, CDK6, VDR, PGE, IL7, WT1, FGF1, BACE1, NOG, TGM2, LRP5, COL1A1, CTSK, TNFRSF11B, PIK3CG, NFATC1, GATA4, CALCA, LCN2, WNT1, TTR, MAP3K1, APAF1, GLB1, COL1A2, DKK1, RAC1, ARSA |
| 4       | 6.909 | 56    | 190   | CDA, PROK2, FABP4, HBB, WAS, GHR1L, PPARA, SLPI, PTH1R, HPRT1, SYK, PRKacbR, SHBG, PRKQ, IGBP3, GNA12, CANT1, H6ST1, NSM, CASR, LTA4H, CTSS, HP, CHIT1, KL, GLI2, OTX2, FGF23, DUT, GNRH1, ALDOA, TAC3, CHD7, BMP6, HSP22, MAPK12, TGFBR2, AHSR, PRLR, FGFB, PDPK1, TAC3, BRAF, MGP, KISS1R, MMP8, CTS5, CDK2, PROK2R, SULT2A1, HSP90AB1, CNR1, CALM1, TGFBR2, ASA1H, RBP4, RXRA |
| 5       | 6.75  | 9     | 27    | PM2S, ERCC6, ERCC2, CDK7, NBN, RECN4A, RFC2, POLD1, WRN |
| 6       | 4.293 | 42    | 88    | PRKAR1A, NOP10, DTYMK, CYP2C8, TIN2F, DKK1, MLXPL1, STS, HLA-DQB1, IMDPDH2, GSTM1, MTHFR, ARG1, UMP5, HSD17B1, AKR1C3, NR1H4, CLIC1, RT1L1, IAPP, ENPP1, MME, ADH1C, ACE2, CTC1, HLA-DQA1, CYP2C9, PPP1CC, GSTA1, PDE5A, GCK, TK1, GMIPR, BCHE, NHP2, IRF5, PENR, WRAP35, CMA1, GSTM2, ADH1B, RXRB |
| 7       | 4.174 | 24    | 48    | GLO1, CRTAP, APRT, GART, PDEB3, MTHFD1, PNP, FKBP1A, PPIB, BHM1, POUP1F1, GH1, PLD2, LHX4, F11, UCK2, NME2, PDE4B, PDE4D, ADK, PAH, DCK, F12, TYPM |
| 8       | 4     | 14    | 26    | NT5M, PDE3B, YARS, PDE11A, GMIPR2, AKR1C2, AHCY, EPHX2, DAHDH, PEX12, DHFR, AGXT, CRAT, TYMS |
| 9       | 4     | 5     | 8     | B4GALT7, LGALS7, XLT2, B3GALT6, B3GAT3 |
| 10      | 3.5   | 5     | 7     | NR12, CYP27A1, CYP3A4, NRII3, CES1 |
| 11      | 3.077 | 14    | 20    | FECH, GALE, ALDH2, FDPS, POR, SC5D, GNPD2A, SHMT1, PHGDH, GNPD1A, PSEAT1, SDS, ALAD, GATM |
| 12      | 3     | 3     | 3     | RAB5A, FZD4, KIF11, VAMP7, NDP |
| 13      | 3     | 3     | 3     | TP11, PDHB, PKLR |
| 14      | 3     | 3     | 3     | SMS, SRM, OTC |
| 15      | 3     | 3     | 3     | LDHB, AK1, PEPD |
| 16      | 2.857 | 8     | 10    | CD79A, GBA, FKBPI10, PLS3, SERPINH1, SERPINF1, SORD, MALTI |
| 17      | 2.4   | 11    | 12    | GSTP1, FBXW7, GNAS, KAT2B, CALCRL, NOTCH3, WNT16, CYP17A1, SFRP1, CGA, NR3C2 |
null
Figure 5: Bubble chart. (a) Biological processes of cluster 1. (b) Cell components. (c) Molecular function. (d) Signaling pathways; X-axis stands for fold enrichment. (e) Reactome pathways; X-axis stands for FDR. (f) The role of LDD in the Wnt signaling pathway modified from hsa04310.

Figure 6: Pathway of LDD-osteoporosis PPI network. Blue circle stands for osteoporosis gene; pink circle stands for LDD target. Purple circle stands for LDD-osteoporosis targets; green hexagon stands for herb; red diamond stands for signaling pathway.
antiosteoporosis effects [59, 60]. In addition, the metabolites of quercetin upregulate the antioxidant capacity of osteoblasts isolated from the fetal rat skull [61]. PaenNFLorin can regulate osteoclastogenesis and osteoblastogenesis both in vitro and in vivo experiments [62, 63]. (+)-Catechin can significantly inhibit RANKL-induced osteoclastogenesis by inhibiting NF-kB transcriptional activity and nuclear transport [64, 65]. Furthermore, (+)-catechin inhibits IGF-1-induced osteoblast migration via p44/p42 MAP kinase [66]. Dioscin can reduce bone loss by enhancing osteoblast production and inhibiting osteoclastogenesis [67, 68]. Diosgenin also plays a role in antiosteoporosis. It can inhibit osteoclastogenesis, stimulates the osteogenic activity of osteoblasts in vitro, and exerts some antiosteoporosis effects on rats in vivo [69–72]. Ursolic acid primarily regulates the homeostasis of osteoclasts and osteoblasts to regulate osteoporosis [73–75]. Oleanolic acid combined with ursolic acid can increase BMD and improve microstructure in aged female rats, which may be potential candidates for the prevention and treatment of osteoporosis [76]. Loganin, alisol A 24-acetate, and alisol B also have antiosteoporosis effects [77–79].

Through the study of small molecule compounds, we determined the synergy between the main active compounds of LDD in the treatment of osteoporosis. Meanwhile, through the construction and analysis of the network, we obtained important targets for LDD and the potential biological processes and signaling pathways for the treatment of osteoporosis (such as positive regulation of calmodulin 1-monoxygenase activity, estrogen metabolism, endothelial cell proliferation, JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix). However, since the above processes are all completed by computer simulation, experiments are still needed for further verification. Therefore, we used the human transcriptomics data in the GEO database (GSE57273) and protein arrays data in reference [30] for further verification.

3.3. Human Transcriptomics Data Analysis

3.3.1. Human Transcriptomics Data. The transcriptomics data from GSE57273 were collected from GEO. A total of 45220 genes with their data were obtained (Table S9). The genes with log2FC ≥1 or ≤−1 and P-value <0.05 are thought to be differentially expressed genes (Figure 7(a)). The gene expression matrix of osteoporosis-related genes is shown in Figure 7(b); take 50 genes as an example (Table S6).

To further analyze the transcriptomics data, the identified genes with log2FC ≥2 or ≤−2 and P-value <0.01 (significantly differentially expressed genes) were selected. After the selection, a total of 4031 genes were obtained. Finally, the top 3000 genes were selected for enrichment analysis.

3.3.2. Enrichment Analysis for Human Transcriptomics Data. After the enrichment analysis, several biological processes, Reactome pathways, and signaling pathways are obtained. The results of GO enrichment are mainly related to insulin-like growth factor and its receptor signaling pathway (GO: 0048009), extracellular matrix (GO: 0098609), endothelial cell formation (GO:0061028), skeletal system morphogenesis (GO: 0048705), several osteoporosis-related signaling (such as hippo signaling, MAPK signaling, regulation of T-cell receptor signaling pathway), and so on (Figure 8(a)).

The results returned by Reactome pathways enrichment show that LDD is able to regulate Cell-extracellular matrix interactions, Interleukin-7 signaling, SUMOylation of transcription cofactors, SUMOylation of intracellular receptors, Downregulation of TGF-beta receptor signaling, MET activates RAPI and RAC1, Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA, Interleukin-6 signaling, Cohesin Loading onto Chromatin, Interleukin-12 family signaling, and so on (Figure 8(b)).

The results of signaling pathway enrichment are protein processing in the endoplasmic reticulum, TGF-beta signaling pathway, Phosphatidylinositol signaling system, Neurotrophin signaling pathway, Thyroid hormone signaling pathway, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, FoxO signaling pathway, Estrogen signaling pathway, Insulin signaling pathway, and NF-kappa B signaling pathway (Figure 8c). The details of biological processes, Reactome pathways, and signaling pathways are described in Tables S7–S9.

3.4. Protein Arrays Data Analysis

3.4.1. Protein Arrays Data. The osteoporosis-related protein arrays data comes from [30]. The network was constructed by Metascape (Figure 9).

3.4.2. Enrichment Analysis for Protein Arrays Data. Protein arrays data were input into DAVID and Reactome for enrichment analysis and returned several biological processes, Reactome pathways, and signaling pathways. The results of GO enrichment are shown in Figures 10(a)–10(c).

The results of GO enrichment are mainly related to immune response (GO:0060334), cell proliferation (GO: 0045597, GO:0040008, GO:0042127, GO:0007179, GO: 0060395, GO:0060397), and other aspects (GO:1903543, GO: 0010718, GO:0030501) (Figure 10(a)).

The results of signaling pathway enrichment are related to bone homeostasis (such as hsa04630: Jak-STAT signaling pathway, hsa04380:Osteoclast differentiation, and degradation of the extracellular matrix). However, since the above processes are all completed by computer simulation, experiments are still needed for further verification. Therefore, we used the human transcriptomics data in the GEO database (GSE57273) and protein arrays data in reference [30] for further verification.

The results returned by Reactome pathways enrichment are associated with immunomodulatory (such as R-HSA-1280215, R-HSA-449147, R-HSA-6785807, R-HSA-168256, and R-HSA-8877330), cell growth, proliferation, and cell cycle (such as R-HSA-9617828 and R-HSA-452723), transcription factor and coactivated genes that interact with STAT proteins (R-HSA-2173796 and R-HSA-9006936), and other transcription factors and their coactivated genes (R-HSA-2173789 and R-HSA-76002) (Figure 10(c)). The details of biological processes, Reactome pathways, and signaling pathways are described in Tables S10–S12.
In summary, we found that the mechanism of LDD in the treatment of osteoporosis is related to immunity, cell growth and proliferation, endocrine hormones and cytokines, and differentiation of osteoclasts and osteoblasts. These pathways work together to regulate the activity of osteoclasts and balance the process of bone turnover through the interaction of crucial proteins. Next, animal experiments were conducted to verify the mechanism of LDD on osteoporosis.

3.5. Effect of LDD on BMD of Proximal Femur. The BMD of the proximal femur in the model group was lower than that in the sham operation group ($P < 0.01$). The BMD of the proximal femur in the LDD group and the positive control group was higher than that in the model group ($P < 0.01$). Compared with the positive control group, the BMD of the proximal femur in the LDD group was not statistically significant ($P > 0.05$) (Figure 11).

3.6. Effect of LDD on Serum E2 and ALP. Compared with the model group, the serum E2 and ALP of the LDD group were significantly improved ($P < 0.05$), suggesting that LDD can increase serum E2 and ALP levels in osteoporotic rats (Figure 12).

3.7. Effect of LDD on Bone Histopathology. In the sham operation group, dense and regular bone trabeculae were arranged in the bone tissue of the rats, and the morphological structure was complete, and the bone marrow cavity size was normal. Compared with the model group, the trabecular bones of the LDD group were regularly arranged, with few fractures, morphological structure close to normal, and the size of the bone marrow cavity was normal, similar to the sham operation group. It is suggested that LDD can improve the destruction of bone tissue structure in PMOP rats (Figure 13).

3.8. Effect of LDD on Wnt3a and β-Catenin mRNA Expression. Compared with the sham operation group, the Wnt3a and β-catenin mRNA expression of the model group decreased ($P < 0.05$). Compared with the model group, Wnt3a and β-catenin were significantly increased in the LDD group and the positive control group ($P < 0.05$), similar to the sham operation group. It is suggested that LDD can

---

**Figure 7:** Human transcriptomics data. (a) Volcano plot; red point stands for upregulated gene; green point stands for downregulated gene. Black point stands for gene that is not differentially expressed. (b) Gene expression matrix of osteoporosis-related genes.
negative regulation of toll-like receptor 3 signaling pathway
regulation of T cell receptor signaling pathway
microtubule anchoring at centrosome
microvillus assembly
protein targeting to Golgi
establishment of endothelial barrier
positive regulation of glucose import in response to insulin stimulus
negative regulation of JUN kinase activity
platelet-derived growth factor receptor signaling pathway
reactive oxygen species metabolic process
regulation of nitric-oxide synthase activity
positive regulation of VEGF production
hippo signaling
activation of MAPKK activity
reactive regulation of I-kB kinase/NF-kB signaling
nagative regulation of angiogenesis
stem cell population maintenance
positive regulation of fibroblast proliferation
ubiquitin-dependent protein catabolic process
response to endoplasmic reticulum stress
mitotic nuclear division
G2/M transition of mitotic cell cycle
positive regulation of I-kB-signaling
angiogenesis

cell-cell adhesion
TGF-beta signaling pathway
Protein processing in endoplasmic reticulum
Phosphatidylinositol signaling system
Neurotrophin signaling pathway
Focal adhesion
Signaling pathways regulating pluripotency of stem cells
Insulin signaling pathway

Figure 8: Bubble chart of biological processes, Reactome, and signaling pathways. (a) Bubble chart of biological processes; (b) bubble chart of Reactome pathways; (c) bubble chart of signaling pathways. X-axis in A and C stands for fold enrichment and X-axis in B stands for FDR.

Figure 9: Continued.
improve osteoporosis in rats by regulating the expression of Wnt3a and β-catenin (Figure 14).

3.9. Molecular Docking Results of LDD Components and Osteoporosis-Related Gene. Due to the limitations of the prediction database, this study used molecular docking technology to further explore whether the LDD components can directly interact with osteoporosis-related genes. The lowest binding energy between the LDD component and the target protein is less than $-5\text{kJ/mol}$, indicating that the ligand and the receptor can bind spontaneously and stably.
The results are shown in Table 4. The docking mode of LDD components with JAK2, ESR1, and CTNNB1 is shown in Figure 15.

Comparing the pathways of the LDD-osteoporosis PPI network and human transcriptomics data, it was found that the osteoporosis-related pathways they share are TGF-beta signaling pathway, Neurotrophin signaling pathway, Thyroid hormone signaling pathway, FoxO signaling pathway, Estrogen signaling pathway, Insulin signaling pathway, and NF-kappa B signaling pathway. The unique osteoporosis-related pathways in enrichment results of human transcriptomics data were as follows: Protein processing in endoplasmic reticulum, Phosphatidylinositol signaling system, Focal adhesion, and Signaling pathways regulating pluripotency of stem cells. Comparing the pathways of protein arrays data network and LDD-osteoporosis PPI network, it is found that the osteoporosis-related pathways they share are Jak-STAT signaling pathway, TGF-beta signaling pathway, Estrogen signaling pathway, Cytokine-cytokine receptor interaction, and TNF signaling pathway. The unique osteoporosis-related pathways in enrichment results of protein arrays data were as follows: Prolactin signaling pathway and Signaling pathways regulating pluripotency of stem cells [80, 81].

The skeletal structure undergoes subtle changes throughout life, requiring the involvement of osteoblasts and osteoclasts [82]. The two cells interact at the same site on the bone surface, in which osteoclasts are involved in bone resorption, which weakens bone strength and causes osteoporosis when bone resorption is more than bone formation [82]. The current intervention in osteoporosis is to inhibit bone resorption—osteoclast activity regulation [83]. Osteoclasts are matured from mononuclear-macrophage cell lines, mainly regulated by macrophage colony-stimulating factor (MCSF), nuclear stimulating factor-κB receptor ligand (RANKL), and osteoprotegerin (OPG) [84, 85], of which MCSF is a key factor in the
regulation of osteoclast differentiation [86]. Bone biopsy data and in vitro studies have shown that osteoclasts that complete the bone resorption mission will automatically undergo apoptosis, which is one of the mechanisms for the body to maintain bone metabolism balance [86]. The regulation of these cytokines on osteoclast activity is mainly reflected in [87–90]: (1) the auto/paracrine effect of local cells directly regulates the proliferation and differentiation of immature osteoblasts and bone resorption activities; (2) they can indirectly increase the sensitivity of bone resorption associated with parathyroid hormone (PTH); (3) inhibition of osteoclast activity by the interaction of signaling pathways. Among them, the RANKL/RANK system is the most irreplaceable regulation of bone cell unit activity, and various external factors play a role in changing the signaling pathway in this system [86]. For example, L-1a, IL-6, IL-11, IL-16, and PTH can activate the RANKL/RANK system to enhance RANKL expression, thus completing bone remodeling [91]. The signaling pathways associated with the RANKL/RANK system are mainly the NF-κB pathway, MAPK pathway, PI3K/Akt pathway, and CN/NFAT pathway [92]. Hence, the RANKL/RANK system plays a role similar to the common terminal pathway during osteoclast activation; and the drugs designed by the system, such as denosumab, have many advantages in the clinical practice of treating osteoporosis, such as fewer side effects [93].

MCSF is produced by various cells in the bone microenvironment and acts on the osteoclasts in a paracrine manner, resulting in increased expression of genes involved in osteoclast differentiation and increased osteoclast activity [94]. In addition, MCSF can also promote the formation of mature osteoclasts indirectly through the RANKL pathway [94]. Osteoprotegerin (OPG) is mainly expressed on the surface of osteoblasts and inhibits the activation of osteoclasts and its bone resorption activity by competitively inhibiting the binding of RANKL to RANK [95]. Meanwhile, prostaglandins (PGs), metastatic growth factors (TGF-β), interferon (INF), and insulin-like growth factor (IGF) are also associated with the activation of osteoclasts [96].

Hormones also play an important role in the process of bone regulation, especially the regulation of osteoclast activity [97]. For example, estrogen plays an important role in

| Components          | JAK2     | ESR1     | CTNNB1    |
|---------------------|----------|----------|-----------|
| Alisol A            | −20.7207 | −23.4835 | −15.3626  |
| Dioscin             | −15.1115 | −15.9068 | −19.8416  |
| Loganin             | −15.4463 | −16.1161 | −12.1394  |
| Oleanolic acid      | −27.2509 | −27.209  | −22.437   |
| Pachymic acid       | −20.637  | −15.1952 | −13.5626  |
| Ursolic acid        | −27.9625 | −29.3857 | −22.8974  |

Table 4: The binding energy of molecules (kJ/mol).
inhibiting bone resorption, and various forms of hypogonadism that lack estrogen can lead to osteoporosis [97]. The mechanism is that estrogen can act on ERα of osteoclasts, stimulate OPG expression, inhibit the activation of osteoclast-associated cytokine expression, and ultimately reduce the rate of osteoclastogenesis through the RANKL signaling pathway [98]. For this target, the main drugs are selective estrogen receptor modulator (raloxifene) and artificial estrogen to inhibit bone resorption, treat osteoporosis, and at the same time relieve menopausal symptoms in
menopausal women [99]. Other hormones, such as calcitonin, are also associated with inhibition of bone resorption, and their short-term efficacy in the treatment of osteoporosis is obvious, but long-term efficacy is poor [100]. The hormones that act indirectly on bone resorption are PTH and glucocorticoids [101]. The synthetic PTH analog, teriparatide, enhances osteoclast function by promoting the lysosomal enzyme production and acid synthesis in osteoclasts and through the AC/cAMP pathway [101].

Through the construction and enrichment analysis of the predicted target network of small molecule compounds in LDD, we can find that the small molecule compounds of LDD can regulate some biological processes. For example, they can regulate endothelial cell proliferation and neovascularization, bone formation, bone resorption and reconstruction, differentiation of mesenchymal stem cells, formation of extracellular matrix and collagen of bone formation, differentiation of osteoblasts, and osteoclasts, and so on. These biological processes play an important role in the development of osteoporosis. Meanwhile, this study suggests that LDD can regulate some cytokines related to osteoporosis, such as TGF-β, INF, IGF, and calmodulin 1-monoxygenase, which are closely associated with the activation of osteoclasts [94, 102]. The GO enrichment analysis of LDD has also shown that it can regulate the production and metabolism of hormones such as estrogen and glucocorticoids; these hormones can regulate osteoclast activity directly (estrogen) or indirectly (glucocorticoids), thereby regulating bone resorption [103]. The results of the pathway enrichment analysis show that LDD can regulate the FoxO signaling pathway, Estrogen signaling pathway, Osteoclast differentiation, PI3K-Akt signaling pathway, Ras signaling pathway, T-cell receptor signaling pathway, and so on. These pathways are closely related and synergistic, acting together on the bone resorption process, regulating osteoclast activity [104], and ultimately regulating the core mechanism of osteoporosis—bone turnover. The current drug development of osteoporosis has also developed targeted drugs for the above multiple pathways, such as denosumab (for OPG/RANKL/RANK pathway) [105], romosozumab (for Wnt signaling pathway) [106], and rapamycin (for mTOR signaling pathway) [107].

The most important signaling pathways associated with osteoporosis are the OPG/RANKL/RANK signaling pathway, which includes NF-κB signaling, MAPK signaling, PI3K/Akt signaling, and CN/NFAT signaling [92, 96]. The MAPK family pathway mainly includes the extracellular-regulated protein kinase (ERK) signaling pathway, Jun N-terminal kinase (JNK) signaling pathway, the ERK5/macrokinactivating protein kinase signaling pathway, and the p38 signaling pathway [108]. In addition, the signaling pathway with osteoporosis includes PPAR-y [109], Wnt/β-catenin [110], Hedgehog [111], BMP [112], Notch [113], JAK/STAT [114], and TGF-β/SMAD signaling pathway [115].

In conclusion, although this study explored the molecular mechanism of LDD in the treatment of osteoporosis through bioinformatics and systems pharmacology and transcriptomics and verified some related molecular mechanisms, its molecular mechanism still needs to be further elucidated in order to promote the thorough disclosure and elucidation of the molecular network mechanism of LDD in the treatment of osteoporosis.

4. Conclusion

LDD may have a therapeutic effect on osteoporosis through regulating the targets (such as ALB, IGF1, SRC, and ESR1), biological processes (such as positive regulation of calmodulin 1-monoxygenase activity, estrogen metabolism, and endothelial cell proliferation), and pathways (such as JAK-STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) found in this research.

Data Availability

The data that support the findings of this study are available in supplementary materials.

Disclosure

Long Zhi-yong, and Yu Gan-peng should be considered joint first authors.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Long Zhi-yong, Xiang Wang, Yuan Meng-xia, Wu Jia-min, Yu Gan-peng, Yang Tie-jun, and Li Jun are responsible for the study concept and design. Long Zhi-yong, Xiang Wang, Yuan Meng-xia, Wu Jia-min, Yang Tie-jun, Yu Gan-peng, Li Jun, and Wu Yong-he are responsible for data analysis and interpretation. Long Zhi-yong, Xiang Wang, Yuan Meng-xia, Wu Jia-min, and Yang Tie-jun drafted the manuscript; Yu Gan-peng and Li Jun supervised the study; all authors participated in the analysis and interpretation of data and approved the final manuscript.

Acknowledgments

The authors thank Xing Li for assisting with the English translation and writing.

Supplementary Materials

Table S1-1: components meeting the screening criteria. Table S1-2: compound targets for each compound of LDD. Table S2: osteoporosis genes. Table S3: enrichment analysis of clusters based on Gene Ontology (GO) annotation of LDD-osteoporosis PPI network. Table S4: pathway enrichment analysis of LDD-osteoporosis PPI network. Table S5: Reactome pathways of LDD-osteoporosis PPI network. Table S6: Human Transcriptomics Data. Table S7: the biological processes of Human Transcriptomics Data Network.
Table S8: the Reactome pathways of Human Transcriptomics Data Network. Table S9: the signaling pathways of Human Transcriptomics Data Network. Table S10: the biological processes of protein arrays data network. Table S11: the Reactome pathways of protein arrays data network. Table S12: the signaling pathways of protein arrays data network.

(Supplementary Materials)

References

[1] N. E. Lane, “Epidemiology, etiology, and diagnosis of osteoporosis,” American Journal of Obstetrics and Gynecology, vol. 194, no. 2, pp. S3–S11, 2006.

[2] J. Bover, L. Bailone, V. López-Báez et al., “Osteoporosis, bone mineral density and CKD-MBD: treatment considerations,” Journal of Nephrology, vol. 30, no. 5, 2017.

[3] A. Fontalis, E. Kenanidis, R. A. Kotronias et al., “Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss,” Expert Opinion on Pharmacotherapy, vol. 20, no. 9, pp. 1123–1134, 2019.

[4] V. Testini, M. T. Paparella, I. Gangai, and G. Guglielmi, “Postmenopausal osteoporosis: current status of bone densitometry,” Minerva Obstetrici e Ginecologici, vol. 73, no. 6, pp. 730–743, 2021.

[5] J.-G. Zhao, X.-T. Zeng, J. Wang, and L. Liu, “Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults,” JAMA, vol. 318, no. 24, p. 2466, 2017.

[6] K. A. Kennel and M. T. Drake, “Adverse effects of bisphosphonates: implications for osteoporosis management,” Mayo Clinic Proceedings, vol. 84, no. 7, pp. 632–638, 2009.

[7] C.-T. Che, M. Wong, and C. Lam, “Natural products from Chinese medicines with potential benefits to bone health,” Molecules, vol. 21, no. 3, p. 239, 2016.

[8] C. Li, Q. Li, R. Liu et al., “Medicinal herbs in the prevention and treatment of osteoporosis,” American Journal of Chinese Medicine, vol. 42, no. 1, pp. 1–22, 2014.

[9] J. Bai, “A meta-analysis of the clinical efficacy of liuwei dihuang pill in the treatment of primary osteoporosis of liver and kidney yin deficiency,” Liaoning University of Traditional Chinese Medicine, in Chinese, 2018.

[10] Y. Liu, P. Wang, X. Shi et al., “Liuwei dihuang decoction for primary osteoporosis,” Medicine, vol. 98, no. 16, Article ID e15282, 2019.

[11] Y. Wang, W. Guo, L. Cheng, P. Liu, Z. Xia, and H. Wang, “The effect of liuwei dihuang pill on the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis,” Chinese Journal of Osteoporosis, vol. 26, no. 5, 2020.

[12] J.-r. Ge, L.-h. Xie, J. Chen et al., “Liuwei dihuang pill (六味地黄丸) treats postmenopausal osteoporosis with shen (kidney) yin deficiency via janus kinase/signal transducer and activator of transcription signal pathway by up-regulating cardioprophline-like cytokine factor 1 expression,” Chinese Journal of Integrative Medicine, vol. 24, no. 6, pp. 415–422, 2018.

[13] B. Xia, B. Xu, Y. Sun et al., “The effects of liuwei dihuang on canonical Wnt/β-catenin signaling pathway in osteoporosis,” Journal of Ethnopharmacology, vol. 153, no. 1, pp. 133–141, 2014.

[14] W. Chen, J. Wang, J. Shi et al., “Longevity effect of liuwei dihuang in both caenorhabditis elegans and aged mice,” Aging and disease, vol. 10, no. 3, pp. 578–591, 2019.

[15] B. S. Yadav and V. Tripathi, “Recent advances in the system biology-based target identification and drug discovery,” Current Topics in Medicinal Chemistry, vol. 18, no. 20, pp. 1737–1744, 2018.

[16] A. D. Boran and R. Iyengar, “Systems approaches to polypharmacology and drug discovery,” Current Opinion in Drug Discovery & Development, vol. 13, no. 3, pp. 297–309, 2010.

[17] K. Yang, L. Zeng, and J. Ge, “Exploring the pharmacological mechanism of danzhi xiaoyao powder on ER-positive breast cancer by a network pharmacology approach,” Evidence-based Complementary and Alternative Medicine, vol. 2018, Article ID 5059743, 20 pages, 2018.

[18] L. Zeng, K. Yang, and J. Ge, “Uncovering the pharmacological mechanism of astragalus salvia compound on pregnancy-induced hypertension syndrome by a network pharmacology approach,” Scientific Reports, vol. 7, no. 1, Article ID 16849, 2017.

[19] Y. Guo, C. Bao, D. Ma et al., “Network-based combinatorial CRISPR-cas9 screens identify synergistic modules in human cells,” ACS Synthetic Biology, vol. 8, no. 3, pp. 482–490, 2019.

[20] H. Huiying, Z. Linhua, and Z. Bo, “Network pharmacology approach to determine active compounds and action mechanisms of Ge-Gen-Qin-Lian decoction for treatment of type 2 diabetes,” Evidence-based Complementary and Alternative Medicine, vol. 4, no. 3, pp. 1–12, 2014.

[21] F. P. Chen, C. M. Chang, S. J. Hwang, Y. C. Chen, and F. J. Chen, “Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset,” BMC Complementary and Alternative Medicine, vol. 4, no. 3, p. 91, 2014.

[22] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[23] D. Metodiewa, A. Kochman, and S. Karolczak, “Evidence for antiradical and antioxidiant properties of four biologically active N,N-diethylaminoethy l ethers of flavone oximes: a comparison with natural polyphenolic flavonoid rutin action,” JURMB Life, vol. 41, no. 5, pp. 1067–1075, 1997.

[24] L. L. Chen, Y. H. Wang, J. Qi, T. X. Dong, D. N. Zhu, and B. Y. Yu, “Identification and determination of absorbed components of danggui-shaoyao-san in rat plasma,” CJNM, vol. 9, pp. 363–368, 2011.

[25] Y. F. Liu, “Study on reactive substance and function of rehmannia,” Peking Union Medical College, in Chinese, 2013.

[26] D. P. Lu and Y. Wan, “Progress of pharmacological action and clinical application of rehmannia,” Strait Pharm J, vol. 3, pp. 23–26, 2004.

[27] H. W. Li and X. L. Meng, “Research progress on chemical constituents and pharmacological activities of rehmannia glutinosa,” Drug Evaluation and Research, vol. 2, no. 5, pp. 218–228, 2015.

[28] J. Ye, X. Zhang, X. Zhang et al., “Chemical fingerprinting of liuwei dihuang pill and simultaneous determination of its major bioactive constituents by hplc coupled with multiple detections of dad, elsd and esi-ms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 3, pp. 638–645, 2009.

[29] X. F. Liu, S. S. Ouyang, Y. Biao et al., “PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach,” Nucleic Acids Research, vol. 38, 2010.

[30] L. Xie, J. Chen, and S. Li, “Effect of liuweidihuang pill on JAK/STAT signaling pathway gene expression in
postmenopausal osteoporosis with the kidney yin deficiency,” *Chinese Journal of Osteoporosis*, vol. 20, no. 7, pp. 741–746, 2015.

[31] D. Szklarczyk, A. Franceschini, S. Wyder et al., “STRING v10: protein–protein interaction networks, integrated over the tree of life,” *Nucleic Acids Research*, vol. 43, no. D1, pp. D447–D452, 2015.

[32] S. M. Orchard, B. Ammari, and B. Aranda, “The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases,” *Nucleic Acids Research*, vol. 42, 2014.

[33] P. V. Missiuro, K. Liu, L. Zou et al., “Information flow analysis of interactome networks,” *PLoS Computational Biology*, vol. 5, no. 4, Article ID e1000350, 2009.

[34] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” *Nature Protocols*, vol. 4, no. 1, pp. 44–57, 2009.

[35] A. Fabregat, S. Jupe, L. Matthews et al., “The reactome pathway knowledgebase,” *Nucleic Acids Research*, vol. 46, no. D1, pp. D649–D655, 2018.

[36] S. K. Burley, H. M. Berman, G. J. Kleywegt, J. L. Markley, H. Nakamura, and S. Velankar, “Protein data bank (PDB): the single global macromolecular structure archive,” *Methods in Molecular Biology*, vol. 1607, pp. 627–641, 2017.

[37] S. Xu, L. Zhuang, Y. Qu et al., “Material basis and mechanism of erzhi pill for preventing osteoporosis based on network pharmacology,” *Chinese Pharmaceutical Journal*, vol. 53, no. 22, pp. 1913–1920, 2018.

[38] C. G. Yao, C. L. Xi, X. Zhu et al., “Expression, purification, evaluation of activity, and analysis of inhibitor docking of enterovirus 71 3C protease,” *Journal of Pathogens and Biology*, vol. 12, no. 8, pp. 722–726, 2017.

[39] F. H. Liu, S. J. Chen, and W. J. Ni, “Study on the computer virtual screening of anti-thrombotic active ingredients in chuanxiong rhizoma,” *Chinese Pharmaceutical Journal*, vol. 28, no. 16, pp. 2182–2186, 2017.

[40] G. Ma, “The effects of liuwei dihuang on canonical Wnt/p-catenin signaling pathway in prevention of osteoporosis induced by ovariectomy,” *Zhejiang Chinese Medical University*, in Chinese, 2015.

[41] J. Chen, L. Xie, and S. Li, “Relationship between JAK/STAT pathway and immunomodulatory effects of liuwei dihuang pills on postmenopausal osteoporosis patients with syndrome of deficiency of kidney yin,” *China Journal of Traditional Chinese Medicine and Pharmacy*, vol. 32, no. 4, pp. 1747–1750, 2017, in Chinese.

[42] S. Xu, “The relationship between the methylation of ERα and kidney deficiency PMOP and intervention of Chinese herbal medicine,” *Guangzhou University of Chinese Medicine*, in Chinese, 2017.

[43] B. Xie, S. Zhang, J. Liu, X. Zhan, D. Xie, and Z. Zhang, “Enhanced estrogenic activity of soybean isoflavones by coadministration of liuwei dihuang pills in ovariectomized rats,” *Phytotherapy Research*, vol. 29, no. 7, pp. 1054–1061, 2015.

[44] W. Gong, N. Zhang, G. Cheng et al., “Rehmannia glutinosa libosch extracts prevent bone loss and architectural deterioration and enhance osteoblastic bone formation by regulating the IGF-1/P13K/mTOR pathway in streptozocin-induced diabetic rats,” *International Journal of Molecular Sciences*, vol. 20, no. 16, pp. 3964, 2019.

[45] N. Lai, J. Zhang, X. Ma et al., “Regulatory effect of catalpol on Th1/Th2 cells in mice with bone loss induced by estrogen deficiency,” *American Journal of Reproductive Immunology*, vol. 74, no. 6, pp. 487–498, 2015.

[46] Y. Zhu, Y. Wang, Y. Jia, J. Xu, and Y. Chai, “Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/b-catenin pathway,” *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 37, 2019.

[47] S. Sassa, T. Kikuchi, H. Shinoda, S. Suzuki, H. Kudo, and S. Sakamoto, “Preventive effect of ferulic acid on bone loss in ovariectomized rats,” *In Vivo*, vol. 17, no. 3, pp. 277–280, 2003.

[48] T. Sagar, M. Ranthla, M. C. Kruger, M. Coetzee, and V. Deepak, “Ferulic acid impairs osteoclast fusion and exacerbates survival of mature osteoclasts,” *Cytotechnology*, vol. 68, no. 5, pp. 1963–1972, 2016.

[49] N. Raut, S. M. Wicks, T. O. Lawal, and G. B. Mahady, “Epigenetic regulation of bone remodeling by natural compounds,” *Pharmacological Research*, vol. 147, Article ID 104350, 2019.

[50] H.-Y. Tsai, H.-Y. Lin, Y.-C. Fong et al., “Paenol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-κB pathway,” *European Journal of Pharmacology*, vol. 588, no. 1, pp. 123–133, 2008.

[51] C.-H. Tsai, M.-H. Hsu, P.-H. Huang et al., “A paenol derivative, YPH-PA3 promotes the differentiation of monocytic/macrophage lineage precursor cells into osteoblasts and enhances their autophagy,” *European Journal of Pharmacology*, vol. 832, pp. 104–113, 2018.

[52] S. Adhikary, D. Choudhary, N. Ahmad et al., “ Dietary flavonoid kaempferol inhibits glucocorticoid-induced bone loss by promoting osteoblast survival,” *Nutrition*, vol. 53, pp. 64–76, 2018.

[53] B. Nowak, A. Matuszewska, A. Nikodem et al., “Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteoporosis,” *Pharmacological Reports*, vol. 69, no. 5, pp. 1113–1119, 2017.

[54] M. R. Byun, H. Jeong, S. I. Bae, A. R. Kim, E. S. Hwang, and J.-H. Hong, “TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol,” *Bone*, vol. 50, no. 1, pp. 364–372, 2012.

[55] C.-J. Kim, S.-H. Shin, B.-J. Kim et al., “The effects of kaempferol-inhibited autophagy on osteoclast formation,” *International Journal of Molecular Sciences*, vol. 19, no. 1, p. 125, 2018.

[56] E. M. Choi, “Kaempferol protects MC3T3-E1 cells through antioxidant effect and regulation of mitochondrial function,” *Food and Chemical Toxicology*, vol. 49, no. 8, pp. 1800–1805, 2011.

[57] L. Yang, B. Zhang, J. Liu et al., “Protective effect of acteoside on ovariectomy-induced bone loss in mice,” *International Journal of Molecular Sciences*, vol. 20, no. 12, p. 2974, 2019.

[58] S.-Y. Lee, K.-S. Lee, S. H. Yi, S.-H. Kook, and J.-C. Lee, “Acteosides suppresses RANKL-mediated osteoclastogenesis by inhibiting c-fos induction and NF-κB pathway and attenuating ROS production,” *PLoS One*, vol. 8, no. 12, Article ID e80873, 2013.

[59] W. Liang, Z. Luo, S. Ge et al., “Oral administration of kaempferol inhibits glucocorticoid-induced bone loss in rat model of ovariectomy-induced osteoporosis,” *Stem Cell Research & Therapy*, vol. 10, no. 1, pp. 317–324, 2011.

[60] L.-z. Xing, H.-j. Ni, and Y.-l. Wang, “Quercitrin attenuates osteoporosis in ovariectomized rats by regulating mitogen-activated protein kinase (MAPK) signaling pathways,” *Biomedicine & Pharmacotherapy*, vol. 89, no. 1, pp. 1136–1141, 2017.
Evidence-Based Complementary and Alternative Medicine

[61] J. G. Messer, R. G. Hopkins, and D. E. Kipp, "Quercetin metabolites up-regulate the antioxidant response in osteoblasts isolated from fetal rat calvaria," Journal of Cellular Biochemistry, vol. 116, no. 9, pp. 1857–1866, 2015.

[62] Y. Wang, J. Dai, Y. Zhu et al., "Paeoniflorin regulates osteoclastogenesis and osteoblastogenesis via manipulating NF-xb signaling pathway both in vitro and in vivo," Oncotarget, vol. 9, no. 7, pp. 7372–7388, 2017.

[63] Y. Wang, Y. Zhu, S. Lu, C. Hu, W. Zhong, and Y. Chai, "Beneficial effects of paeoniflorin on osteoporosis induced by high-carbohydrate, high-fat diet-associated hyperlipidemia in vivo," Biochemical and Biophysical Research Communications, vol. 498, no. 4, pp. 981–987, 2018.

[64] J.-H. Lee, H. Jin, H.-E. Shim, H.-N. Kim, H. Ha, and Z. H. Lee, "Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-fos expression and suppressing the nuclear factor-xb signal," Molecular Pharmacology, vol. 77, no. 1, pp. 17–25, 2010.

[65] S.-T. Chen, L. Kang, C.-Z. Wang et al., "(−)-Epigallocatechin-3-gallate decreases osteoclastogenesis via modulation of RANKL and osteoprotegrin," Molecules, vol. 24, no. 1, p. 156, 2019.

[66] T. Kawabata, H. Tokuda, G. Sakai et al., "Repression of IGF-I-induced osteoblast migration by (−)-epigallocatechin gallate through p44/p42 MAP kinase signaling," Biomedical Reports, vol. 2, pp. 318–326, 2018.

[67] X. Tao, Y. Qi, L. Xu et al., "Dioscin reduces ovarectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis," Pharmacological Research, vol. 108, pp. 90–91, 2016.

[68] X. Qu, Z. Zhai, X. Liu et al., "Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades," Biochemical and Biophysical Research Communications, vol. 443, no. 2, pp. 658–665, 2014.

[69] J. Folwarczna, M. Zych, B. Nowińska et al., "Effect of diosgenin, a steroidal sapogenin, on the rat skeletal system," Acta Biochimica Polonica, vol. 63, no. 2, pp. 287–295, 2015.

[70] S. Zhao, F. Niu, C.-Y. Xu et al., "Diosgenin prevents bone loss on retinoic acid-induced osteoporosis in rats," Irish Journal of Medical Science, vol. 185, no. 3, pp. 581–587, 2016.

[71] Z. Zhang, C. Song, X. Fu et al., "High-dose diosgenin reduces bone loss in ovariectomized rats via attenuation of the RANKL/OPG ratio," International Journal of Molecular Sciences, vol. 15, no. 9, pp. 17130–17147, 2014.

[72] Z. Zhang, Y. Chen, L. Xiang, Z. Wang, G. Xiao, and D. Ju, "Diosgenin protects against alveolar bone loss in ovariectomized rats via regulating long non-coding RNAs," Experimental and Therapeutic Medicine, vol. 16, no. 5, pp. 3939–3950, 2018.

[73] S. Lee, S. Park, H. Kwak, J. Oh, Y. Min, and S. Kim, "Anabolic activity of ursolic acid in bone: stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo," Pharmacological Research, vol. 58, pp. 290–296, 2008.

[74] M. Cheng, X.-h. Liang, Q.-w. Wang, Y.-t. Deng, Z.-x. Zhao, and X.-y. Liu, "Ursolic acid prevents retinoic acid-induced bone loss in rats," Chinese Journal of Integrative Medicine, vol. 25, no. 3, pp. 210–215, 2019.

[75] H. Tan, C. Zhao, Q. Zhu et al., "Ursolic acid isolated from the leaves of loquat (eriobotrya japonica) inhibited osteoclast differentiation through targeting exportin 5," Journal of Agricultural and Food Chemistry, vol. 67, no. 12, pp. 3333–3340, 2019.

[76] S. Cao, X.-L. Tian, W.-X. Yu et al., "Oleanolic acid and ursolic acid improve bone properties and calcium balance and modulate vitamin D metabolism in aged female rats," Frontiers in Pharmacology, vol. 9, no. 1, p. 1435, 2018.

[77] M. Li, W. Wang, F. Wang, K. Yang, H. Sun, and X. Wang, "The pharmacological effects of morroniside and loganin isolated from Liuweidihuang Wan, on MC3T3-E1 cells," Molecules, vol. 15, no. 10, pp. 7403–7414, 2010.

[78] K.-J. Kim, A. S. Leoutou, J.-T. Yeon et al., "The inhibitory effect of alisol A 24-acetate fromAlisma canaliculatum osteoclastogenesis," International Journal of Endocrinology, vol. 2015, Article ID 132436, 7 pages, 2015.

[79] J.-W. Lee, Y. Kobayashi, Y. Nakamichi et al., "Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice," Biochemical Pharmacology, vol. 80, no. 3, pp. 352–361, 2010.

[80] M. Kanehisa, Y. Sato, M. Furumichi, K. Morishima, and M Tanabe, "New approach for understanding genome variations in KEGG," Nucleic Acids Research, vol. 47, no. 1, pp. D590–D595, 2019.

[81] M. Kanehisa and S. Goto, "KEGG: kyoto encyclopedia of genes and genomes," Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000.

[82] R. Eastell and P. Szulc, "Use of bone turnover markers in postmenopausal osteoporosis," Lancet Diabetes & Endocrinology, vol. 5, no. 11, pp. 908–923, 2017.

[83] D. M. Black and C. J. Rosen, "Postmenopausal osteoporosis," New England Journal of Medicine, vol. 374, no. 3, pp. 254–262, 2016.

[84] M. Tsubaki, T. Satou, T. Itoh et al., "Bisphosphonate-and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2," Molecular and Cellular Endocrinology, vol. 361, pp. 219–231, 2012.

[85] F. Martín-Saavedra, L. Crespo, C. Escudero-Duch, L. Saldáña, E. Gómez-Barrena, and N. Vilaboa, "Substrate microarchitecture shapes the paracrine crosstalk of stem cells with endothelial cells and osteoblasts," Scientific Reports, vol. 7, no. 1, Article ID 15182, 2017.

[86] Z. H. Li, Y. Si, G. Xu et al., "High-dose PMA with RANKL and MCSF induces THP-1 cell differentiation into human functional osteoclasts in vitro," Molecular Medicine Reports, vol. 16, no. 6, pp. 8380–8384, 2017.

[87] M. Asagiri and H. Takayanagi, "The molecular understanding of osteoclast differentiation," Bone, vol. 40, no. 2, pp. 251–264, 2007.

[88] L. I. Plotkin and A. Bruzzaniti, "Molecular signaling in bone cells: regulation of cell differentiation and survival," Advances in Protein Chemistry and Structural Biology, vol. 116, no. 3, pp. 237–281, 2019.

[89] D. S. Amarasekara, H. Yun, S. Kim, N. Lee, H. Kim, and J. Rho, "Regulation of osteoclast differentiation by cytokine networks," Immune Network, vol. 18, no. 1, p. e8, 2018.

[90] J. H. Park, N. K. Lee, and S. Y. Lee, "Current understanding of RANK signaling in osteoclast differentiation and maturation," Molecules and Cells, vol. 40, no. 10, pp. 706–713, 2017.

[91] V. Nagy and J. M. Penninger, "The RANKL-RANK story," Gerontology, vol. 61, no. 6, pp. 534–542, 2015.

[92] S. Khosla, "Mini review: the OPG/RANKL/RANK system," Endocrinology, vol. 142, no. 12, pp. 5050–5055, 2001.

[93] H. G. Bone, R. B. Wagman, M. L. Brandi et al., "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM
trial and open-label extension,” *Lancet Diabetes & Endocrinology*, vol. 5, no. 7, pp. 513–523, 2017.

[94] B. F. Boyce, “Advances in the regulation of osteoclasts and osteoclast functions,” *Journal of Dental Research*, vol. 92, no. 10, pp. 860–867, 2013.

[95] D. Wagner and A. Fahrleitner-Pammer, “Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?” *Wiener Medizinische Wochenschrift*, vol. 160, pp. 452–457, 2010.

[96] X. Chen, Z. Wang, N. Duan, G. Zhu, E. M. Schwarz, and C. Xie, “Osteoblast-osteoclast interactions,” *Connective Tissue Research*, vol. 59, no. 2, pp. 99–107, 2018.

[97] T. Miyamoto, “Mechanism underlying post-menopausal osteoporosis: HIF1α is required for osteoclast activation by estrogen deficiency,” *Keio Journal of Medicine*, vol. 64, no. 3, pp. 44–47, 2015.

[98] C. Brown, “Staying strong,” *Nature*, vol. 550, no. 7674, pp. S15–S17, 2017.

[99] R. G. G. Russell, “Pharmacological diversity among drugs that inhibit bone resorption,” *Current Opinion in Pharmacology*, vol. 22, no. 3, pp. 115–130, 2015.

[100] S. H. Tella and J. C. Gallagher, “Prevention and treatment of postmenopausal osteoporosis,” *Journal of Steroid Biochemistry and Molecular Biology*, vol. 142, no. 3, pp. 155–170, 2014.

[101] W. Misiorowski, “Parathyroid hormone and its analogues—molecular mechanisms of action and efficacy in osteoporosis therapy,” *Endokrynologia Polska*, vol. 62, no. 1, pp. 73–78, 2011.

[102] W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast differentiation and activation,” *Nature*, vol. 423, no. 6937, pp. 337–342, 2003.

[103] T. Rharass and S. Lucas, "Mechanisms in endocrinology: bone marrow adiposity and bone, a bad romance?" *European Journal of Endocrinology*, vol. 179, no. 4, pp. R165–R182, 2018.

[104] H. Choi, G.-J. Kim, H.-S. Yoo et al., “Vitamin C activates osteoblastogenesis and inhibits osteoclastogenesis via wnt/β-catenin/ATF4 signaling pathways,” *Nutrients*, vol. 11, no. 3, p. 506, 2019.

[105] A. S. K. Sølling, T. Harssløf, and B. Langdahl, "Current status of bone-forming therapies for the management of osteoporosis," *Drugs & Aging*, vol. 36, no. 7, pp. 625–638, 2019.

[106] F. Cosman, D. B. Crittenden, J. D. Adachi et al., "Romosozumab treatment in postmenopausal women with osteoporosis," *New England Journal of Medicine*, vol. 375, no. 16, pp. 1532–1543, 2016.

[107] G. Shen, H. Ren, T. Qiu et al., "Mammalian target of rapamycin as a therapeutic target in osteoporosis," *Journal of Cellular Physiology*, vol. 233, no. 5, pp. 3929–3944, 2018.

[108] G. L. Johnson and R. Lapadat, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases," *Science*, vol. 298, no. 5600, pp. 1911-1912, 2002.

[109] Y. Li, D. Jin, W. Xie et al., "PPAR-γ and Wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively," *Current Stem Cell Research and Therapy*, vol. 13, no. 3, pp. 185–192, 2018.

[110] M. Rossini, D. Gatti, and S. Adami, "Involvement of WNT/β-catenin signaling in the treatment of osteoporosis," *Calcified Tissue International*, vol. 93, no. 2, pp. 121–132, 2013.

[111] X. Li, Q. Jie, H. Zhang et al., "Disturbed MEK/ERK signaling increases osteoclast activity via the hedgehog-gli pathway in postmenopausal osteoporosis," *Progress in Biophysics and Molecular Biology*, vol. 122, no. 2, pp. 101–111, 2016.

[112] G. Sánchez-Duffhues, C. Hiepen, P. Knaus, and P. Ten Dijke, "Bone morphogenetic protein signaling in bone homeostasis," *Bone*, vol. 80, no. 4, pp. 43–59, 2015.

[113] S. Zanotti and E. Canalis, "Mechanisms in endocrinology: notch signaling in skeletal health and disease," *European Journal of Endocrinology*, vol. 168, no. 6, pp. R95–R103, 2013.

[114] L. Xu, L. Zhang, H. Zhang et al., "The participation of fibroblast growth factor 23 (FGF23) in the progression of osteoporosis via JAK/STAT pathway," *Journal of Cellular Biochemistry*, vol. 119, no. 5, pp. 3819–3828, 2018.

[115] N. Che, W. Qiu, J. K. Wang et al., "MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway," *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 8, pp. 3183–3189, 2019.